Skip to content

Systematic development and validation of an exacerbation risk index for COPD patients in general practice: tailoring treatment to an individual*s needs

Systematic development and validation of an exacerbation risk index for COPD patients in general practice: tailoring treatment to an individual*s needs - ICE COLD ERIC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32202
Enrollment
220
Registered
2008-04-17
Start date
2008-04-08
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Experts currently see COPD as a systemic illness, not just as a pulmonary illness chronic bronchitis lung emphysema

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients *40 years of age with COPD in GOLD stage II to IV (postbronchodilator FEV1/FVC*0.70, postbronchodilator FEV1*80% predicted are eligible if in- or outpatient treatment of their last exacerbation ended *4 weeks ago. If patients had an exacerbation in the previous 4 weeks, (s)he can be invited when free of exacerbations for at least 4 weeks. We will include any patient who is able to complete the baseline assessment.

Exclusion criteria

Exclusion criteria: We will exclude patients who received mechanical ventilation in the previous 12 months because of their extremely poor prognosis and patients with co-morbidities associated with a life expectancy of *12 months. We will also exclude patients diagnosed with dementia, psychosis or other psychiatric illness that invalidate assessment of patient-reported parameters (health-related quality of life, physical activity, dyspnea etc). Finally, we will exclude patients if the baseline assessment including the questionnaires cannot be completed due to language difficulties.

Design outcomes

Primary

MeasureTime frame
Exacerbations and health-related quality of life

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)